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Abstract
Background—Wilms tumor (WT) is thought to arise in children of black African ancestry with
greater frequency than whites. To clarify the biological basis for race disparities in WT, we first
verified that black children residing in Tennessee have an increased incidence of WT, and second,
established molecular profiles in WT that are specific to race.
Materials and Methods—To assess race disparities in WT epidemiology, the Tennessee
Cancer Registry (TCR) was queried for all in-state patients less than 20 years of age and registered
between 1999–2008. To explore race disparities in WT biology, six black and four white WT
specimens acquired in Tennessee were analyzed using imaging mass spectrometry (IMS).
Results—TCR data show that black children are overrepresented among WT patients (29%)
relative to all other childhood cancers (18.5%; p=0.01). WT ranked the 5th most common cancer
diagnosis among blacks, but 9th among whites. The diagnosis of WT occurred 79% more
frequently among blacks (n=28) than whites (n=69; p=0.01), and proportionally more blacks
tended to present with distant disease. Although overall survival from WT was not statistically
different between blacks (92.9%) and whites (94.0%), black males showed the lowest survival
(85%; p=0.21). IMS analysis identified peptide spectra from both WT blastema and stroma that
independently classify specimens according to race with greater than 80% accuracy.
Conclusions—In Tennessee, black children appear more susceptible than whites to develop
WT. Race-specific molecular profiles can be determined that may help to clarify pathways of
Wilms tumorigenesis and the biological basis for race disparities in WT incidence and biology.
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INTRODUCTION
Wilms tumor (WT) is the most common malignancy arising in the kidney of children, yet its
incidence varies between race groups around the world (1–3). Epidemiologic studies suggest
that race, more than geography or nationality, is a greater risk factor for the development of
WT (2). Specifically, North American children of black African ancestry have an increased
incidence of WT (11 cases per million children less than 15 years of age) compared to
whites (8 cases per million), whereas children of Asian ancestry show the lowest incidence
(3 cases per million) (2, 4). Furthermore, black children born in sub-Saharan Africa show
particularly high incidence rates of WT and experience dismal outcomes (5–7). Although 4-
year survival from WT exceeds 90% in most developed countries, African-American
children, when compared to white Americans, continue to experience lower late survival
from WT despite similar enrollment in treatment protocols (1, 8).
The seminal paper describing race disparities in WT documented a nearly two-fold increase
in its incidence among blacks residing in the Greater Delaware Valley (9). Importantly from
that study, those congenital anomalies that associate with the development of WT (aniridia,
genito-urinary malformations, mental retardation, and disorders of sexual differentiation,
WT1; and the overgrowth syndromes, hemihypertrophy and Beckwith-Wiedemann, WT2)
were shown to occur with greater frequency in blacks. These anomalies when present in
patients who subsequently develop WT have now been associated with loss of
heterozygosity (LOH) at WT1 (11p13) and loss of imprinting (LOI) at WT2 (11p15.5).
However, no specific analysis of racial disparity in the mutational status of either gene in
WT patients has been reported to date. Moreover, no analysis at any molecular level has
been reported attempting to clarify observed race disparities in WT.
The biology and behavior of WT may vary between patients, and several tumor factors have
been identified that correlate with advanced stages of disease and outcome, including
CITED1, telomerase, IGFR-I, topoisomerase II, and CRABP2 (10–15). Microarray studies
have shown further that a number of genes active in nephrogenesis, yet normally
downregulated in the adult kidney, are overrepresented in WT specimens (11, 16).
Activating mutations of β-catenin and WTX also have been described in 15% to 30% of WT
(17–19). Finally, LOH at 1p, 7p and 16q have been identified in a spectrum of WT and
portend worse outcome (20–22). However, an analysis of how these complex molecular
circumstances implicated in WT development and disease progression contribute to racially
disparate incidences and outcomes has not been reported.
To clarify the disparate incidence and behavior of WT between blacks and whites, a formal
biological analysis is needed. First, we verified that race disparities in incidence exist in the
larger population comprising our institutional tissue repository. Second, we performed
imaging mass spectrometry on a sample of our WT tissues to test the hypothesis that WT
show a unique molecular profile specific to race and histologic compartment.
MATERIALS AND METHODS
Tennessee Cancer Registry
In order to validate our strategy to explore the biological basis for race disparities in WT
using specimens archived in our institutional tissue repository, we sought first to confirm
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that Tennessee children indeed show a racially disparate behavior in WT. To evaluate race
disparities in WT within the larger population of children contributing tissues to our
repository, we queried the Tennessee Cancer Registry (TCR) for all cancer cases affecting
residents less than 20 years of age and registered between 1999–2008. Measured variables
included cancer diagnosis, race, gender, stage of disease at presentation, days to first cancer
treatment, length of follow up in days, and vital status. Notably, the TCR defines a cancer
diagnosis according to the International Classification of Childhood Cancer (Third Edition:
ICCC-3) and defines stage of disease according to the Surveillance Epidemiology and End
Results (SEER) summary for stage of disease.
Imaging Mass Spectrometry
Imaging Mass Spectometry (IMS) was used to analyze the proteome of a subset of our
repository WT specimens. To control for sampling error across these often large specimens,
two tissue blocks from the same WT specimen, but remote from one another, were selected
after review of the hematoxylin and eosin (H & E) slides. Blocks were chosen to include
regions of histologic interest, enriched with blastema and tumor stroma, and showing
negligible tumor necrosis. One section from each of two blocks of the last 6 black and 4
white patients treated for WT at our Tennessee institution were submitted for IMS. These
WT patients were matched for primary resection (i.e. no neoadjuvant therapy), favorable
histology, and stage of disease.
IMS was used as previously described (23). Briefly, two serial sections from each specimen
block were cut at 6 μm thickness, and one section of each pair was stained with hematoxylin
and eosin (H & E). Photomicrographs of these 20 H & E slides were marked for 300 μm
diameter histologic regions of histologic interest within blastemal and stromal compartments
(Figure 1: blastema, teal; stroma, pink). Tissue sections for mass spectrometry analysis were
deparaffinized and subjected to heat-induced antigen retrieval. Digital images of the stained
sections were matched to the corresponding unstained serial sections using Photoshop
(Adobe, San Jose, CA). Coordinates of the histological annotations were determined and
transferred to an acoustic robotic microspotter for deposition of trypsin and α-cyano-4-
hydroxycinnamic acid matrix (10 mg/ml in 50:49.9:0.1 acetonitrile:water:trifluoroacetic
acid). Spectra were collected using a Bruker UltrafleXtreme mass spectrometer equipped
with a SmartBeam™ laser (Bruker Daltonics, Billerica, MA). Each spectrum was the sum of
1600 laser shots collected throughout the entire area of each matrix spot. The data were
preprocessed (baseline subtraction, noise level estimation, and alignment to common peaks),
and classifiers were determined using a support vector machine algorithm.
To demonstrate feasibility in the sequencing of peptides that are unique to either race group,
fragmentation (MS/MS) spectra were generated from statistically relevant peaks obtained
directly from the tissue section. MS/MS spectra were submitted to Mascot software (Matrix
Science, Boston, MA) for database searching to determine the amino acid sequence and
parent protein identity of the peptides.
Statistical Analysis
Statistical analysis of TCR data was performed using SAS statistical package (SAS, Raleigh,
NC). Specific tests are reported with results. Statistical significance was set at p<0.05. For
IMS data, statistical analyses between race groups were accomplished by feeding data into
ClinPro Tools statistical analysis software package (Bruker Daltonics). Peak picking was
performed manually to assure proper peak boundaries and selection of only the
monoisotopic peak. Unsupervised clustering, principal component analyses, and receiver
operating characteristics (ROC) were performed to classify peptide spectra according to
race. Peptides with an area under the curve from the ROC plots of greater than 0.8 were
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considered significant. To determine accuracy of protein sequencing data, an ion’s score is
−10*Log(P), where P is the probability that the observed match is a random event. For the
peptide discussed below, individual ion scores greater than 37 indicate peptides with
significant homology, whereas individual ion scores greater than 47 indicate identity or
extensive homology (p<0.05).
RESULTS
Demographics of the Tennessee Cancer Registry Cohort
After exclusion of other race groups, 2,515 cancer patients (black, n=475; white, n=2,040)
less than 20 years of age were registered in the TCR as in-state residents for the study
period, and 97 had WT (black, n=28; white, n=69). A rank order of ICCC-3 site/histology
codes was generated and showed that WT was the 5th most common cancer arising in black
children, but was only 9th for whites (Table 1). With the exception of Site Group XI, all
other site/histology codes ranked similarly between the two race groups.
To assess disparity in WT incidence between race groups, TCR data showed that blacks
were overrepresented among WT patients (29%) relative to all other cancer types (18.5%;
Mantel-Haenszel χ2 p=0.01; Table 2). The diagnosis of WT was 79% more likely to occur
among black cancer patients than whites (Odds ratio 1.79, 95% CI 1.14–2.81; p=0.01). This
ratio represents the increased odds for black cancer patients less than 20 years of age to be
diagnosed with WT relative to all other forms of cancer and, importantly, does not reflect
risk to the general population. Gender did not affect this increased incidence in WT among
Tennessee blacks, as the white male to black male incidence ratio was 0.70, and the white
female to black female ratio was 0.74.
Stage of Wilms Tumor at Presentation
To assess disparity in the stage of WT at presentation, stage of disease data showed that
more black children (25%) diagnosed with WT tended to present with distant disease than
did whites (15%; p=0.26, Mantel-Haenszel χ2). Among children presenting with distant
disease for all cancer types, black patients were diagnosed more frequently with WT (3.5%)
than whites (1.4%; Fisher’s Exact Test, p=0.047; Table 3). Importantly, and consistent with
previous reports, the median age at presentation of WT tended to be older for blacks
(4.1±0.9 years) than whites (3.2±0.4 years; Kruskal-Wallis, p=0.06).
Survival
To evaluate disparate outcomes between these race groups, overall survival from WT was
not statistically different between blacks (92.9%) and whites (94.0%) residing and treated in
Tennessee, although black males showed the lowest survival (85%) for race-gender
subgroups (p=0.21, Fisher’s Exact Test).
Time from WT Diagnosis to Initiation of Therapy
To determine whether a disparity in initiation of cancer therapy for WT between race groups
existed in Tennessee, we compared days from diagnosis to first therapeutic intervention for
WT patients. Blacks were treated within a mean of 1.4±0.6 days and whites within 3.0±1.4
days (ANOVA; p=0.46). Median length of recorded follow-up was not statistically different
between race groups either: blacks were followed to 245 days (interquartile range, 200–547
days) and whites to 195 days (IQR, 87–352 days; Wilcoxon Rank Sum, p<0.08). Taken
together, no difference in time from diagnosis to initial treatment was found in this cohort of
Tennessee WT patients.
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IMS of Tennessee WT Specimens
To begin to clarify the biological basis for these race disparities in Tennessee WT patients,
we performed independent IMS analyses of blastemal and stromal histologic compartments
in WT specimens derived from black and white patients. We chose to analyze separately
these two distinct histologic compartments to control for differences in protein composition
of tissues segregating solely according to racial ancestry. Unsupervised clustering of peptide
spectra from either cellular compartment was able to classify tumors according to race with
greater than 80% accuracy (Figure 2: (A) blastema; (B) stroma). Sections from separate
tissue blocks in the same patient clustered adjacent to one another with the exception of one
patient (Figure 2). Importantly, these peptide spectra from either histologic compartment
were distinct from one another, suggesting race and cancer cell specificity of the WT
proteome. Principal component analysis was used to identify peptide peaks within blastemal
and stromal compartments that could discriminate WT specimens according to race (Figure
3: (A) blastema; (B) stroma).
Peptide identification and sequencing detected proteins that appear differentially expressed
in WT blastema between race groups. For example, ACTG1, a protein active in cell motility,
was uniquely detected in blastema of tissues from white patients with extensive homology
(Figure 4: (A) sequencing data of ACTG1; (B) individual ions scores > 47 indicate identity,
p<0.05).
DISCUSSION
These TCR data suggest that WT is more of a health concern for blacks than whites residing
in Tennessee. Importantly, these TCR data support previous studies that document an
increased incidence of WT to develop in children of black African ancestry, regardless of
residence in geographically disparate regions of the world, and implicate a racial
predisposition to develop WT. Coupled with the mass spectrometry data generated from two
distinct cellular compartments within racially diverse specimens, it appears that a race-
specific biology may be at play in both the tumorigenesis and pathogenesis of WT.
This study provides two important contributions to the understanding of race disparities in
both WT epidemiology and biology. First, regarding epidemiology, this study represents the
initial description of how WT incidence and behavior may differ between race groups from
Tennessee, which serves as a surrogate for the greater South Region. To monitor population
cancer trends in the United States, the National Cancer Institute established the Surveillance,
Epidemiology and End Results (SEER) Program. The SEER registry accounts for
approximately 26% of the US population, but does not include our population in Tennessee.
Furthermore blacks comprise only 7.3% of SEER registered patients. The South Region, as
designated by the United States Census Bureau, is comprised of 17 states, where collectively
56% of the African-American population resides. However, only three states in this South
Region, Georgia, Kentucky and Louisiana, contribute data to the SEER registry. Therefore,
SEER data may be insufficient to evaluate race disparities in a rare cancer such as WT and
may blur geographical variations in, and region-specific environmental modifiers of, its
incidence. This limitation of the SEER database provides additional rationale to explore
variation in cancer epidemiology between race groups registered in a state cancer database.
Although our study does not have the power to show statistically significant differences in
survival from WT, the race-gender subgroup in the TCR having the lowest survival was
black male. Larger reports have shown that blacks lag whites in late survival from WT,
between 2 and 4% (1, 8). In our cohort, we did not identify any disparities between race
groups in the initiation of WT therapy or in early follow up, although compliance with late
follow up could not be assessed. Notably, a report from the National Wilms Tumor Study
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Group showed that blacks are at significant risk to become lost to follow up, which certainly
could confound any outcome data (1). Nevertheless, the TCR does capture all deaths of its
registrants. A study to investigate race disparities in compliance with late survivorship clinic
evaluation and in chronic health issues of survivors is warranted. Factors that could
influence these disparate outcomes from WT include divergent access to routine preventive
medicine and a delayed age at presentation. Although not statistically significant
observations, black children in our relatively small TCR cohort of WT patients showed both
a more advanced age and stage of disease at presentation, which could reflect delays or
inequalities in access to and provision of routine health care.
A query of a state cancer registry can be meritorious to assess regional trends and race
disparities in malignant diseases, yet this analysis of TCR data has several limitations.
Specifically, the TCR does not record all features known to influence WT behavior, which
could differ according to race and therefore account for the disparate behavior observed
between study groups. As a result, we could not assess disparities in the frequency of
favorable or unfavorable histology, in Children’s Oncology Group (COG) pathologic
staging, and in disease-relapse, considerations that are standard to any WT study. As well,
factors that are widely considered prognostic determinants of WT behavior, such as
mutations of 1p, 7p, 16q WT1, WT2, and WTX, are not measureable currently through the
TCR. Finally, the influence of environmental modifiers and of societal barriers to preventive
medicine for generations of underrepresented minorities was not discernible.
The second unique aspect of this study is underscored by the attempt to clarify the biological
basis for race disparities in a childhood cancer documented within the same population. To
explore the biologic underpinnings of these race disparities in WT epidemiology, we chose
to perform a proteomic analysis of WT between race groups. Matrix Assisted Laser
Desorption Ionization Time of Flight (MALDI-TOF) Imaging Mass Spectrometry (IMS) has
been shown recently to be an innovative, high-throughput means to analyze the proteome of
formalin fixed, paraffin embedded tissues, the most common means of specimen archiving
(23). For these reasons, we postulated that MALDI-TOF-IMS could help tease apart unique
patterns of protein expression that vary according to race and may reflect biologic
differences in the development and behavior of WT along racial lines. Importantly, to
control for histologic differences between specimens having cellular heterogeneity, as is
typical of WT, IMS permits the proteomic analysis of specific cellular compartments within
a tumor (24). For example, comparisons can be made between cell-specific WT
compartments across multiple specimens (e.g. blastema versus blastema; epithelia versus
epithelia; stroma versus stroma), so that variability in histologic subtypes of individual
specimens does not confound peptide spectral differences between grouped samples. As
evident in the current study, the capacity of peptide spectra from two distinct histologic
compartments to classify independently WT specimens according to race ensures that the
observed patterns of protein expression are specific to the cancer cell type and are not
surrogate markers of other biologically unique aspects of race. This ability of MALDI-TOF-
IMS peptide spectra to classify WT specimens according to race represents an early peek
into the biological basis for the current and previous epidemiologic observations discussed
above. Taken together, WT appears to display specific peptide profiles that could account
for its variability in incidence and behavior observed between race groups.
Although encouraging, the preliminary nature of our molecular studies also limits
interpretation of this report. We are currently validating these initial observations with
increased numbers of racially disparate WT specimens both from Vanderbilt and the COG.
Importantly, to evaluate the biological basis for race disparities in adverse WT behavior, half
of these COG specimens derive from patients who subsequently experienced disease-
relapse.
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As the first report to describe race disparities in WT from the South Region, our study
supports previous work that race, more than geographic region, predisposes to the
development of WT, further suggesting a heritable and disparate biology between race
groups. The mass spectrometry data provide initial evidence that a race-specific biology may
indeed underlie observed disparities in WT development and behavior. Through our more
detailed and ongoing molecular analysis, perhaps we can begin to identify peptide spectra
that correlate with, or specific proteins that contribute to, the increased incidence of WT
among children of black African ancestry, as reflected by the TCR data and the larger body
of literature. Such molecular knowledge will help to discover race-specific targets of future,
more personalized WT therapies, which can be further tailored to the risk for specific race
groups to experience adverse behavior and disease-relapse, as also predicted by tumor-
specific molecular fingerprints. Our exploration of the biological basis for race disparities in
a rare childhood cancer could serve as a paradigm for the investigation of other racially
disparate cancers in both children and adults. Additional studies are warranted to clarify the
effect of genetic and epigenetic variability on race disparities in WT.
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Hematoxylin and eosin staining of a representative Wilms tumor specimen. (A) Cellular
compartments of blastema (teal) and tumor stroma (pink) are marked for IMS analysis. (B)
Higher power image of marked histologic regions within rectangle in (A).
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Unsupervised clustering of all peptide spectra from (A) blastema and (B) stroma is able to
classify Wilms tumor specimens according to race (B = black and W = white patient tumor
specimens). The asterisks (*) in (A) indicate the only patient whose tumor specimens did not
cluster immediately next to one another.
Axt et al. Page 10














Example of a principal component analysis of peptide peaks within (A) blastema and (B)
stroma that discriminate Wilms tumor specimens according to race.
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Peptide identification and sequencing detects proteins that appear differentially expressed in
Wilms tumor according to race. (A) sequencing of ACTG1. (B) individual ions scores > 47
indicate identity, p<0.05).
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Table 1
International Classification of Childhood Cancer, 3rd edition Race Race
Black Rank White Rank
Cancer Type n n
Site Group I: Leukemias, Myeloproliferative & Myelodysplastic Diseases 109 1 491 1
Lymphoid Leukemias 70 351
Acute Myeloid Leukemias 29 80
Other 10 60
Site Group II: Lymphomas & Reticuloendothelial Neoplasms 65 3 260 3
Hodgkins Lymphomas 32 146
Non-Hodgkins Lymphoma (Except Burkitt’s) 31 73
Burkitt’s Lymphoma * 25
Other * 16
Site Group III: CNS & Miscellaneous Intracranial & Intraspinal Neoplasms 80 2 337 2
Astrocytomas 37 173
Intracranial & Intraspinal Embryonal Tumors 16 72
Other 27 92
Site Group IV: Neuroblastoma & Other Peripheral Nerve Cell Tumors 22 7 97 8
Neuroblastoma & Ganglioneuroblastoma 22 97
Site Group V: Retinoblastoma 9 9 35 10
Retinoblastoma 9 35
Site Group VI: Renal Tumors 34 5 80 9
Wilms Tumor 28 69
Other 6 11
Site Group VII: Hepatic Tumors 1 11 19 11
Hepatoblastoma * 19
Site Group VIII: Malignant Bone Tumors 22 7 101 7
Ewing’s Sarcoma & Related Sarcomas of Bone 0 36
Osteosarcomas 21 57
Other * 8
Site Group IX: Soft Tissue & Other Extraosseous Sarcomas 39 4 135 5
Rhabdomyosarcomas 16 66
Other 23 69
Site Group X: Germ Cell Tumors, Trophoblastic Tumors & Neoplasms of Gonads 24 6 104 6
Malignant Gonadal Germ Cell Tumors 16 81
Other Germ Cell Tumors 8 23
Site Group XI: Other Malignant Epithelial Neoplasms & Malignant Melanomas 19 10 179 4
Other 19 179
Total cases reported in this table 433 1838
Total childhood cancer cases with behavior code 3 (invasive) 444 1863
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